フィブリノリシン(人)

フィブリノリシン(人) 価格

フィブリノリシン(人) 化学特性,用途語,生産方法

• 外観

  液体

• 使用

  Plasmin is present in blood to prevent unwanted clotting by catalysing the breakdown of the fibrin polymer that provides the framework of a blood clot. Plasmin is formed from plasminogen, a process that occurs after plasminogen has been activated by forming a complex with fibrin. After certain tissue fragments had been shown to possess plasminogenactivating ability, a soluble fraction possessing this activity was extracted and purified. Cloning and expression of complementary DNA (cDNA) for human tissue-type plasminogen activator permitted commercial production of alteplase.
  Alteplase was shown to be a potent thrombolytic agent by virtue of its ability to activate plasminogen, thus breaking down fibrin in the thrombus. An early clinical study in patients with coronary occlusion following myocardial infarction showed that it was an effective drug for dissolving clots in coronary arteries. It was marketed for this purpose in 1988.

• 定義

  A proteolytic enzyme that dissolves fibrin and hastens the solution of clots that may form in the bloodstream. It is prepared by activating a fraction of normal human plasma with highly purified streptokinase.

• 一般的な説明

  Fibrinolysin

フィブリノリシン(人) 上流と下流の製品情報

フィブリノリシン(人) 生産企業

Global(77)Suppliers

9001-90-5, フィブリノリシン(人) キーワード